Clinical trials: Herpes Simplex Labialis
Herpes Labialis
Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis
To compare safety and efficacy of Perrigo's antiviral drug product compared to an FDA approved antiviral drug product in the treatment of cold sores.
- Trial name
- NCT02265913
- Testing
- Acyclovir 5 percent (Perrigo), Acyclovir 5 percent (Reference)
- Where
- United States
- Volunteers
- 4,076 people
- Sponsor
- Padagis LLC
Herpes Simplex
Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection
This study will evaluate the safety and blood levels of a new pediatric formulation of Famvir in children 1-12 years of age. In Part A, patients will receive a single dose of famciclovir (12.5 mg/kg) to assess pharmacokinetics…
- Trial name
- NCT00098059
- Testing
- Famciclovir
- Where
- 13 sites in United States, Panama
- Volunteers
- 74 people
- Sponsor
- Novartis Pharmaceuticals
Acne, Bites
Implementation of a Minor Ailment Service in Community Pharmacy Practice
Self-care and self-medication are commonly the treatments of choice for the management of minor ailments. Minor ailments can be treated through community pharmacy using a Minor Ailment Service (MAS).
- Conditions
- Acne, Bites, Burns, Cold
- Trial name
- INDICA+PRO (NCT05247333)
- Testing
- Minor ailment service
- Where
- Spain
- Volunteers
- 20,987 people
- Sponsor
- Universidad de Granada
Herpes Simplex
A Safety And Tolerability Study Of Valaciclovir Oral Suspension In Infants And Children
Limited data are available on valaciclovir use in children and valaciclovir is not currently approved for use in pediatrics. The marketed formulation of valaciclovir is not ideal for use in pre-adolescent patients who may have…
- Trial name
- NCT00297206
- Testing
- Valaciclovir
- Where
- 13 sites in United States, Chile and 1 more
- Volunteers
- 36 people
- Sponsor
- GlaxoSmithKline
Anogenital Herpes, COVID-19
Viral Infections in Healthy and Immunocompromised Hosts
Background: Viral infections are an important cause of illness and death in hospitalized patients as well as outpatients. New strains of viruses may appear and infect both healthy people and those with weak immune systems.
- Conditions
- Anogenital Herpes, COVID-19, Herpes Labialis
- Trial name
- NCT01306084
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Photodynamic Therapy, Herpes Simplex, Labial
Treatment of Herpes Labialis by Photodynamic Therapy
Lesions of herpes labialis are caused by the herpes simplex virus type 1 (HSV-1) and cause pain and aesthetic compromise. It is characterized by the formation of small vesicles that coalesce and rupture forming extremely painful…
- Trial name
- Herpes (NCT04037475)
- Testing
- photodynamic therapy herpes labialis
- Where
- Brazil
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Nove de Julho
Herpes Labialis
Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old
To test the safety of Xerese (acyclovir and hydrocortisone)Cream 5%/1% for the treatment of recurrent cold sores in children ages 6-11yrs after 5 days of treatment.
- Trial name
- NCT01574612
- Testing
- acyclovir/hydrocortisone cream
- Where
- 10 sites in United States
- Volunteers
- 54 people
- Sponsor
- Meda Pharmaceuticals
Herpes Labialis
Safety Study of ME-609 for Treatment of Herpes Simplex Labialis in Adolescents
The Purpose of this study is to evaluate the safety of ME-609 for the treatment of recurrent herpes labialis in adolescents.
- Trial name
- NCT00375570
- Testing
- ME-609
- Volunteers
- 254 people
- Sponsor
- Medivir
Herpes Labialis
Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis
This study will assess the safety, tolerability of a single 1500 mg dose of famciclovir in 50 adolescents with recurrent herpes labialis.
- Trial name
- NCT00878072
- Testing
- Famciclovir
- Where
- 12 sites in United States
- Volunteers
- 53 people
- Sponsor
- Novartis Pharmaceuticals